Novo Nordisk's Next Act Hinges on Two Clocks: An FDA Verdict and a Profit Line That Cuts Both Ways

Novo Nordisk investors are juggling two very different timelines. One is regulatory and stretches into 2027. The other is already ticking inside the latest quarterly report, where a striking gap has opened between the Danish drugmaker's adjusted and reported profit.

Start with the near term. Novo Nordisk said on Wednesday that adjusted operating profit climbed 27% at constant exchange rates in the third quarter of 2026, reaching DKK 31.720 million — a pace well ahead of the top line. Revenue for the period came in at DKK 79.195 million, up 4% at constant currencies, with the obesity franchise expanding 22%.

The reported figure tells a different story. Operating profit on an IFRS basis fell 9% at constant exchange rates, dragged down by non-cash impairment charges of DKK 8.7 billion. That divergence is the crux of the debate: whether the underlying earnings momentum is durable enough to outweigh the write-downs showing up in the headline number.

Guidance Moves in the Right Direction — With Room to Fall

Management nudged its full-year outlook higher on Wednesday. For 2026, Novo now expects adjusted revenue and adjusted operating profit at constant exchange rates to land anywhere between a 2% decline and 2% growth. The prior guidance had pointed to a drop of as much as 6%, or flat performance at best.

The revision tilts the expected range favorably, though it still leaves room for contraction. For bulls, the key test is whether the company can actually deliver on that improved outlook and keep the adjusted earnings engine running faster than sales. A confirmation through subsequent quarterly numbers would carry more weight than the guidance itself.

A Scientific Chief's Share Sale Adds Noise

Sentiment got an extra jolt from a disclosure published yesterday. Martin Holst Lange, Executive Vice President and Chief Scientific Officer, sold 12,000 B shares at DKK 285.00 apiece on Wednesday, according to media reports. The stock posted a daily move of -4.1% yesterday.

An executive sale alongside a raised forecast makes for mixed signals, and investors will have to weigh which one speaks louder. Those betting on a continued operational upswing need confidence in future earnings power; the more cautious will focus on the charges still weighing on reported results.

The Obesity Portfolio Is Doing the Heavy Lifting — Unevenly

Beneath the headline numbers, the shape of the obesity business matters. In the third quarter of 2026, US revenue from the Wegovy injection fell 13% at constant exchange rates. The pill and the injection combined, however, grew 21% in that market — evidence that a new delivery format has so far more than offset the decline of an older one.

The pressure extends beyond Wegovy. Ozempic revenue slipped 5% worldwide at constant currencies in the quarter, and 11% in the US. Novo's ability to paper over those soft spots with fresh offerings is precisely what the next product cycle must prove.

CagriSema: A 2027 US Launch, If the FDA Agrees

That is where CagriSema enters the picture. The once-weekly injection pairs semaglutide with cagrilintide, and CEO Mike Doustdar told Bloomberg on Wednesday that a US launch in early 2027 is possible if approval arrives by the end of 2026. Novo is already laying groundwork — manufacturing, staff training and direct distribution through e-health channels and NovoCare — to move quickly should regulators give the green light. CagriSema remains investigational; both approval and timing are open.

The clinical case has substance. In REDEFINE 1, adults without type-2 diabetes achieved average weight loss of 20.4–22.7% after 68 weeks. REDEFINE 2 showed roughly 13.7% loss in people with type-2 diabetes, while REDEFINE 9 delivered 21% at 68 weeks. The head-to-head REIMAGINE 5 trial in type-2 diabetes put CagriSema at 12.4% weight loss versus 9.1% for tirzepatide at a 5 mg dose. On HbA1c reduction, CagriSema demonstrated non-inferiority after 60 weeks. Reported side effects were predominantly gastrointestinal — a factor that will feed into the FDA's overall risk-benefit assessment.

Two Clocks, One Decision

The investment case now resolves in stages. First comes the regulatory verdict, which Novo has not pinned to a firm date. Then comes the commercial question: whether CagriSema generates incremental demand and a genuine additional revenue stream, or merely arrives late while the Wegovy pill keeps compensating for declines elsewhere.

A delayed approval or a pushed-back launch would stretch the period in which existing products must carry the load, sharpening the importance of the adjusted-profit trajectory holding up. Should the FDA decide favorably by the end of 2026, the early-2027 US rollout Doustdar sketched becomes the base case — and demand, rather than the calendar, becomes the number that matters.